Gene targeting of components of the fibrinolytic system

Thrombosis and Haemostasis

Volumn 87, Issue 1, 2002, Pages 22-31

  Ploplis, Victoria A ^a   Castellino, Francis J ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Blood; Fibrinolysis; Gene deficiencies; Hemostasis

Indexed keywords

FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; UROKINASE RECEPTOR;

ADULTHOOD; ANGIOGENESIS; BLOOD CLOT LYSIS; CANCER; CELL GROWTH; EXPERIMENTAL MODEL; FIBRINOLYSIS; GENE DELETION; GENE TARGETING; GENETIC DISORDER; HEMOSTASIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MOBILIZATION; MOUSE; NIDATION; NONHUMAN; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; REVIEW; SURVIVAL; TUMOR GROWTH; VASCULARIZATION; WOUND HEALING;

EID: 0036145706     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1612938     Document Type: Review

References (110)

1. Plasminogen activator inhibitor-1 gene-deficient mice
2. The plasminogen activator/plasmin system
3. Mechanisms of trophoblast invasiveness and their control: The role of proteases and protease inhibitors
4. Hormone regulation of tissue-type plasminogen activator gene expression and plasminogen activator-mediated proteolysis
5. Physiological consequences of loss of plasminogen activator function in mice
6. Plasminogen activator in mouse and rat oocytes: Induction during meiotic maturation
7. Suppression of ovulation rate by antibodies to tissue-type plasminogen activator and alpha 2-antiplasmin
8. Plasminogen activator and mouse spermatozoa: Urokinase synthesis in the male genital tract and binding of the enzyme to the sperm cell surface
9. Plasminogen activators in tissue remodeling and invasion: mRNA localization in mouse ovaries and implanting embryos
10. Implantation. The role of proteinases and blockage of implantation by proteinase inhibitors
11. Plasminogen activator in early embryogenesis: Enzyme production by trophoblast and parietal endoderm
12. Mouse ovarian granulosa cells produce urokinase-type plasminogen activator, whereas the corresponding rat cells produce tissue-type plasminogen activator
13. Biological effects of combined inactivation of plasminogen activator and plasminogen activator inhibitor-1 gene function in mice
14. Effects of disruption of the plasminogen gene on thrombosis, growth, and health in mice
15. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction
16. Growth and behavioral development in plasminogen gene-targeted mice
17. Ligneous conjunctivitis in plasminogen-deficient mice
18. Human homozygous type I plasminogen deficiency and ligneous conjunctivitis
19. Ligneous conjunctivitis in a girl with severe type I plasminogen deficiency
20. Homozygous mutations in the plasminogen gene of two unrelated girls with ligneous conjunctivitis
21. Compound-heterozygous mutations in the plasminogen gene predispose to the development of ligneous conjunctivitis
22. Oral lesions indicative of plasminogen deficiency (hypoplasminogenemia)
23. Resolution of spontaneous bleeding events but failure of pregnancy in fibrinogen-deficient mice
24. A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice
25. The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility
26. Generation and characterization of urokinase receptor-deficient mice
27. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator
28. 2-Antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding
29. The plasminogen activator inhibitor-2 gene is not required for normal murine development or survival
30. Restoration of thrombolytic potential in plasminogen-deficient mice by bolus administration of plasminogen
31. The receptor for urokinase type plasminogen activator polarizes expression of the protease to the leading edge of migrating monocytes and promotes degradation of enzyme inhibitor complexes
32. Concomitant secretion of prourokinase and a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages
33. Intracellular localization of human monocyte associated-interleukin (IL-1) activity and release of biologically active IL-1 from monocytes by trypsin and plasmin
34. Inactive secreted forms of transforming growth factor β: Activation by proteolysis
35. Plasminogen deficiency differentially affects recruitment of inflammatory cell populations in mice
36. Streptokinase-producing streptococci grown in human plasma acquire unregulated cell-associated plasmin activity
37. A surface protease and the invasive character of plague
38. Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model
39. Urokinase-type plasminogen activator in inflammatory cell recruitment and host defense against Pneumocystis carinii in mice
40. Urokinase is required for T lymphocyte proliferation and activation in vitro
41. Urokinase-type plasminogen activator-deficient mice are predisposed to staphylococcal botryomycosis, pleuritis, and effacement of lymphoid follicles
42. Urokinase receptor-deficient mice have impaired neutrophil recruitment in response to pulmonary Pseudomonas aeruginosa infection
43. The plasminogen activation system enhances brain and heart invasion in murine relapsing fever borreliosis
44. Host urokinase-type plasminogen activator participates in the release of malaria merozoites from infected erythrocytes
45. Plasminogen activators are not required in the erythrocytic life cycle of malaria parasites
46. Delayed mortality and attenuated thrombocytopenia associated with severe malaria in urokinase- and urokinase receptor-deficient mice
47. Interaction of a group A streptococcus within human plasma results in assembly of a surface plasminogen activator that contributes to occupancy of surface plasmin binding structures
48. Interaction between group A streptococci and the plasmin(ogen) system promotes virulence in a mouse skin infection model
49. Kringle 2 mediates high affinity binding of plasminogen to an internal sequence in streptococcal surface protein PAM
50. Molecular cooperation between protein PAM and streptokinase for plasmin acquisition by streptococcus pyogenes
51. Role of pleiotropic effects of plasminogen deficiency in infection experiments with plasminogen-deficient mice
52. Impaired arterial neointima formation in mice with disruption of the plasminogen gene
53. Endoluminal arterial injury in plasminogen deficient mice
54. Urokinase but not tissue plasminogen activator mediates arterial neointima formation in mice
55. Receptor-independent role of urokinase-type plasminogen activator in pericellular plasmin and matrix metalloproteinase proteolysis during vascular wound healing in mice
56. Alpha(2)-antiplasmin gene deficiency in mice does not affect neointima formation after vascular injury
57. Inhibiting role of plasminogen activator inhibitor-1 in arterial wound healing and neointima formation: A gene targeting and gene transfer study in mice
58. Plasminogen activator inhibitor-1 deficiency protects against atherosclerosis progression in the mouse carotid artery
59. Remodeling of the vessel wall after copper-induced injury is highly attenuated in mice with a total deficiency of plasminogen activator inhibitor-1
60. Reduced transplant arteriosclerosis in plasminogen-deficient mice
61. Plasminogen is not required for neointima formation in a mouse model of vein graft stenosis
62. Plasminogen deficiency accelerates vessel wall disease in mice predisposed to atherosclerosis
63. Fibrinogen deficiency is compatible with the development of atherosclerosis in mice
64. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice
65. Impaired wound healing in mice with a disrupted plasminogen gene
66. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator
67. Loss of fibrinogen rescues the pleiotropic effects of plasminogen deficiency
68. Persistent corneal haze after excimer laser photokeratectomy in plasminogen-deficient mice
69. Healing of corneal epithelial defects in plasminogen- and fibrinogen-deficient mice
70. Plasminogen deficiency leads to impaired remodeling after toxic injury in to the liver
71. Disruption of plasminogen gene in mice abolishes wound healing after myocardial infarction
72. Liver regeneraton is transiently impaired in urokinase-deficient mice
73. Extracellular proteolysis in the adult murine brain
74. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus
75. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator
76. Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin
77. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin
78. Tissue plasminogen activator-mediated fibrinolysis protects against axonal degeneration and demyelination after sciatic nerve injury
79. Reduction in surface urokinase receptor forces malignant cells into a protracted state of dormancy
80. Expression of the plasminogen activation system in kidney cancer correlates with its aggressive phenotype
81. Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and WT mice: Cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals
82. Direct evidence of the importance of stromal urokinase plasminogen activator (uPA) in the growth of an experimental human breast cancer using a combined uPA gene-disrupted and immunodeficient xenograft model
83. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1
84. Absence of host plasminogen activator inhibitor-1 prevents cancer invasion and vascularization
85. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies
86. Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma
87. Growth and dissemination of Lewis lung carcinoma in plasminogen-deficient mice
88. Fibrinogen is an important determinant of the metastatic potential of circulating tumor cells
89. Reduced metastasis of polyoma virus middle T antigen-induced mammary cancer in plasminogen-deficient mice
90. Coagulation and renal disease
91. The effect of defibrination on macrophage participation in rabbit nephrotoxic nephritis: Studies using glomerular culture and electron microscopy
92. Defibrination with ancrod in experimental immune complex nephritis
93. The effect of defibrination on nephrotoxic serum nephritis in rabbits
94. Glomerular fibrinolytic activity in antiGBM glomerulonephritis in rabbits
95. Plasminogen activator inhibitor 1 in renal deposits of human nephropathies
96. Plasminogen and plasminogen activators protect against renal injury in crescentic glomerulonephritis
97. Abnormalities of pathways of fibrin turnover in lung lavage of rats with oleic acid and bleomycin-induced lung injury support alveolar fibrin deposition
98. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome
99. Local abnormalities of coagulation and fibrinolytic pathways that promote alveolar fibrin deposition in the lungs of baboons with diffuse alveolar damage
100. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1
101. Partial reversal of established bleomycin-induced pulmonary fibrosis by rh-urokinase in a rat model
102. Treatment of bleomycin-induced pulmonary fibrosis by transfer of urokinase-type plasminogen activator genes
103. The development of bleomycin-induced pulmonary fibrosis in mice deficient for components of the fibrinolytic system
104. A total fibrinogen deficiency is compatible with the development of pulmonary fibrosis in mice
105. Bleomycin-induced pulmonary fibrosis in fibrinogen-null mice
106. Etiology and pathogenesis of rheumatoid arthritis
107. Fibrin and fibronectin in rheumatoid synovial membrane and rheumatoid synovial fluid
108. Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis
109. Enhanced expression of genes involved in coagulation and fibrinolysis in murine arthritis
110. Exacerbation of antigen-induced arthritis in urokinase-deficient mice